Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
Russell Moser(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Christopher J. Kemp(Fred Hutch Cancer Center), Cliff Whatcott(Translational Genomics Research Institute), Craig Dorrell(Oregon Health & Science University), Haiyong Han(Translational Genomics Research Institute), Calvin J. Kuo(Stratford University), Olga Nikolova(Oregon Health & Science University), Eduardo Méndez, Kim Moran‐Jones(NHS Greater Glasgow and Clyde), Carla Grandori(Precision for Medicine (United States)), Daniel D. Von Hoff(Translational Genomics Research Institute), Rosalie C. Sears(Oregon Health & Science University), Andrew V. Biankin(University of Glasgow), Kay E. Gurley(Fred Hutch Cancer Center), J. Annis(Fermi National Accelerator Laboratory)
Cited by 0
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration
|Nature|2013|1.6k
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
|Genes & Development|2000|1.4k